Drug intelligence / Profile preview

KJ-C2526

Development stage: Preclinical
Lead developer: CARsgen Therapeutics
Modality: Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KJ-C2526 is an investigational universal allogeneic CAR-T cell therapy developed using the THANK-uCAR platform by CARsgen Therapeutics. It targets NKG2D ligands (NKG2DL), which are stress-induced proteins commonly expressed on the surface of malignant cells and senescent cells. The therapy is being developed for the treatment of acute myeloid leukemia (AML), other malignancies, and cellular senescence. As a universal CAR-T product, it is designed to be used off-the-shelf rather than being patient-specific. The THANK-uCAR platform enables enhanced persistence and antitumor activity in vivo[1][3][6].

Targets

MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on KJ-C2526.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ-C2526.

Explore the full profile